{{Rsnum
|rsid=717620
|Gene=ABCC2
|Chromosome=10
|position=101542578
|Orientation=minus
|GMAF=0.1763
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 0.9 | 34.5 | 64.6
| HCB | 3.6 | 32.8 | 63.5
| JPT | 5.3 | 30.1 | 64.6
| YRI | 0.0 | 6.1 | 93.9
| ASW | 0.0 | 7.0 | 93.0
| CHB | 3.6 | 32.8 | 63.5
| CHD | 6.5 | 27.8 | 65.7
| GIH | 0.0 | 13.9 | 86.1
| LWK | 0.0 | 5.5 | 94.5
| MEX | 1.7 | 41.4 | 56.9
| MKK | 0.6 | 9.0 | 90.4
| TSI | 2.9 | 33.3 | 63.7
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs717620
|Name_s=ABCC2: ?24C>T
|Gene_s=ABCC2, NANOGP6
|Feature=5' UTR, NA
|Evidence=PubMed ID:19940846
|Annotation=The AUCs of irinotecan, SN-38, SN-38 glucuronide, and APC are influenced by rs3740066, rs2306283, rs35605, rs10276036, and rs717620 .
|Drugs=irinotecan; SN-38
|Drug Classes=
|Diseases=
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA165111617
}}

{{PharmGKB
|RSID=rs717620
|Name_s=ABCC2:(-)24C>T
|Gene_s=ABCC2, NANOGP6
|Feature=5' UTR, NA
|Evidence=PubMed ID:17502832
|Annotation=Shows decreased function in vitro, and is associated with several complications.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA161145026
}}

{{PharmGKB
|RSID=rs717620
|Name_s=ABCC2: 5'UTR (-)24C>T, mRNA 118C>T
|Gene_s=ABCC2, NANOGP6
|Feature=5' UTR, NA
|Evidence=PubMed ID:19890249
|Annotation=Risk or phenotype-associated allele: 5&apos;UTR (-)24C>T, mRNA 118C>T. Phenotype: In patients who received cyclosporine in addition to mycophenylate mofetil (MMF), there was a trend toward an association between the ABCC2 C-24T SNP and mycophenolic acid (MPA) AUC(0-12 h), but without any apparent additive effect: carriers of the CT genotype were associated with higher MPA AUC(0-12 h) compared with TT and CC homozygotes. Study size: 115. Study population/ethnicity: Caucasian cohort from the SOPHIE study cotreated with mycophenylate mofetil (MMF) and cyclosporine. Significance metric(s): p = 0.0087. Type of association: GN; PK
|Drugs=cyclosporine; mycophenolate mofetil; mycophenolic acid
|Drug Classes=
|Diseases=Organ Transplantation
|Curation Level=Curated
|PharmGKB Accession ID=PA165109801
}}

{{PMID Auto
|PMID=21451505
|Title=Effect of ABCC2 (MRP2) Transport Function on Erythromycin Metabolism
}}

{{PMID Auto
|PMID=22630058
|Title=ABCC2 Polymorphisms and Haplotype are Associated with Drug Resistance in Chinese Epileptic Patients
}}

{{PMID|17997497}} Association of the multidrug-resistance-associated protein gene (ABCC2) variants with intrahepatic cholestasis of pregnancy.

{{PMID|18926681}} Polymorphisms of MRP2 (ABCC2) are associated with susceptibility to nonalcoholic fatty liver disease.

{{PMID|19568750|OA=1
}} MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer.

{{PMID|20061166}} Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patients.

{{PMID|20139798}} ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.

{{PMID|22318656|OA=1
}} Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry.

{{PMID|22473764}} A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis.

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs717620
|overall_frequency_n=1613
|overall_frequency_d=10758
|overall_frequency=0.149935
|n_genomes=17
|n_genomes_annotated=0
|n_haplomes=18
|n_articles=3
|n_articles_annotated=3
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23506516
|Title=A systematic review and meta-analysis of the role of ABCC2 variants on drug response in patients with epilepsy
}}

{{PMID Auto
|PMID=22868256
|Title=A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen.
|OA=1
}}

{{PMID Auto
|PMID=23069858
|Title=Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy.
}}

{{PMID Auto
|PMID=24782687
|Title=Multi-institutional Study of Outcomes After Pediatric Heart Transplantation: Candidate Gene Polymorphism Analysis of ABCC2
|OA=1
}}

{{PMID Auto
|PMID=25007187
|Title=Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia
}}
{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}